October 12, 2011
Merck (known as MSD outside the US and Canada) received on October 7 approval from the US FDA for Juvisync, a fixed dose combination drug of its DPP-4 inhibitor Januvia (sitagliptin) for the treatment of type 2 diabetes and the...read more